<unk> , sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015, for both indications. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Luspatercept
Teprotumumab
Bezlotoxumab
Dostarlimab
Sacituzumab govitecan
Trafermin
Lestaurtinib
Tralokinumab